Eyevensys closes on $30 million Series B financing

Eyevensys, a Paris-based biotechnology company, has closed a round of $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis, according to a press release.

The funds will be used to launch the phase 2 Electro study of EYS606 in the United States, as well as to further advance preclinical development of other proteins targeted for use in retinal and other ophthalmic diseases.

EYS606, which uses the company’s proprietary electrotransfection system to sustain therapeutic proteins delivered into the ciliary muscle, is in phase 1/2 clinical trials in Europe and has received orphan drug designation from the European Medicines Agency for the treatment of noninfectious uveitis.

“As we launch the Electro study, our first U.S. clinical trial, Eyevensys will also have an opportunity to connect with ophthalmology opinion leaders in the U.S. to gain further exposure for our groundbreaking technology platform,” CEO Patricia Zilliox, PhD, said in the release.

Eyevensys, a Paris-based biotechnology company, has closed a round of $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis, according to a press release.

The funds will be used to launch the phase 2 Electro study of EYS606 in the United States, as well as to further advance preclinical development of other proteins targeted for use in retinal and other ophthalmic diseases.

EYS606, which uses the company’s proprietary electrotransfection system to sustain therapeutic proteins delivered into the ciliary muscle, is in phase 1/2 clinical trials in Europe and has received orphan drug designation from the European Medicines Agency for the treatment of noninfectious uveitis.

“As we launch the Electro study, our first U.S. clinical trial, Eyevensys will also have an opportunity to connect with ophthalmology opinion leaders in the U.S. to gain further exposure for our groundbreaking technology platform,” CEO Patricia Zilliox, PhD, said in the release.